CN Bio Innovations, a cell culture company that has developed organ-on-chip laboratory instruments to improve the accuracy and efficiency of drug discovery, has announced it has raised $9 million USD (circa £6.9 million GBP) investment, led by CITIC Securities Investment Co., Ltd., and supported by existing investor CN Innovations Holdings Ltd.CN Bio’s micro-physiological systems are designed to enable researchers to study drug metabolism, toxicology and specific disease models on single- and multi-organ systems. Providing efficiencies for pre-clinical drug testing with predictive human tissue-based data, CN Bio’s OOC technologies are able to replicate the micro-environments, cell-cell interactions and biological processes that occur in vivo, to reliably bridge the gap between traditional cell culture assays and human studies, improving drug discovery while reducing research and development costs.

Learn more (opens external site)

 

Comments are closed.

Submit a Team Connection

Click here to submit a new Bioinspired Design Connection (you must be logged in first).

Browse Team Connections

Choose by category, team or week:

BioDesign Connections by Category (2020 – 2022)

by Team (2022 only)

by Week (2022 only)

Most Recent Connections

Connection Interactions

Recent Comments

  1. to reduce the impact of car accidents, it may be possible to study the force diverting physics of cockroaches to…

Top Voted Connections